Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

Core Viewpoint - Titan Pharmaceuticals, Inc. is moving forward with a proposed merger with TalenTec Sdn. Bhd., as indicated by the filing of a registration statement on Form F-4 with the SEC [1][2]. Group 1: Merger Details - The merger between Titan and TalenTec is structured as a "reverse merger" transaction, following a Merger Agreement established on August 19, 2024 [1]. - The Business Combination is subject to approval by Titan stockholders and is expected to close in the third quarter of 2025, although this timeline is not guaranteed [3]. Group 2: Regulatory Filings - Black Titan Corporation, the holding company for the merger, has filed the registration statement on Form F-4, which includes a preliminary proxy statement/prospectus [2][4]. - Once the registration statement is effective, a definitive Proxy Statement/Prospectus will be sent to Titan's stockholders for their vote on the Business Combination [4]. Group 3: Participant Information - Titan, TalenTec, and their respective management may be considered participants in the solicitation of proxies from Titan's stockholders regarding the merger [5]. - Detailed information about the officers and directors of both companies will be included in the registration statement and the Proxy Statement/Prospectus [5].